Description
Cagrilintide Research Peptide (10 mg)
Cagrilintide is a synthetic, long-acting amylin analogue engineered through extensive structural modification of human islet amyloid polypeptide (hIAPP, amylin), a 37-amino acid peptide co-secreted with insulin from pancreatic β-cells. Native amylin has a short circulating half-life and a strong propensity for amyloid fibril formation; cagrilintide was designed to overcome both limitations while retaining and enhancing amylin receptor pharmacology.
Cagrilintide has been characterized in peer-reviewed research and clinical investigation as a potent, selective amylin receptor agonist with an extended pharmacokinetic profile suitable for once-weekly dosing paradigms. It has been studied extensively as a research tool for investigating central amylin receptor signaling, energy homeostasis regulation, and glycemic modulation in preclinical metabolic models.
Structural Characteristics
Cagrilintide retains the 37-amino acid backbone length of native amylin but incorporates multiple strategic modifications. The amyloidogenic core sequence of hIAPP (residues 20–29, known as the FGAILS region) has been substituted to eliminate β-sheet aggregation propensity—a critical requirement for generating a stable, injectable research compound. Additional substitutions throughout the sequence optimize receptor binding geometry and resistance to proteolytic degradation.
The most structurally distinctive feature of cagrilintide is its C18 fatty diacid conjugation, attached via a hydrophilic linker to a lysine side chain. This fatty acid moiety enables reversible, non-covalent albumin binding in the systemic circulation, dramatically extending plasma half-life relative to both native amylin and earlier pramlintide analogues. The C-terminal amide of native amylin is preserved, as is the N-terminal disulfide-bridged ring structure (Cys2–Cys7), both of which are required for full amylin receptor efficacy.
Characterized Signaling Pathways
Published research has identified multiple receptor-mediated signaling interactions:
AMY1R / AMY2R / AMY3R (Calcitonin Receptor–RAMP Complexes)
Amylin receptors are heterodimeric complexes formed by the calcitonin receptor (CTR) in association with receptor activity-modifying proteins RAMP1, RAMP2, or RAMP3, yielding AMY1R, AMY2R, and AMY3R subtypes respectively. Cagrilintide acts as a potent agonist at these complexes, activating Gs-coupled adenylyl cyclase and elevating intracellular cAMP, with downstream PKA activation and CREB-mediated transcriptional effects. AMY1R and AMY3R are the predominant subtypes expressed in the area postrema and hypothalamic nuclei relevant to energy balance regulation (Hay et al., British Journal of Pharmacology, 2015).
Area Postrema / Nucleus Tractus Solitarius Satiety Signaling
The area postrema (AP) and nucleus tractus solitarius (NTS) in the brainstem are primary sites of amylin receptor expression and represent key nodes through which amylin analogues reduce food intake. Electrophysiological and c-Fos mapping studies in rodent models have demonstrated that amylin receptor activation in these regions inhibits gastric emptying, reduces meal size, and activates downstream satiety circuits projecting to the hypothalamic arcuate nucleus (Lutz et al., Physiology & Behavior, 2010).
Hypothalamic Energy Homeostasis (ARC–PVN Axis)
Amylin receptor signaling in the arcuate nucleus (ARC) and paraventricular nucleus (PVN) of the hypothalamus modulates neuropeptide Y (NPY), AgRP, POMC, and CART expression, intersecting with leptin and GLP-1 receptor signaling networks. Research has characterized cagrilintide’s capacity to engage these circuits additively with GLP-1 receptor agonists, providing a mechanistic basis for combinatorial metabolic research paradigms (Enebo et al., The Lancet, 2021).
Glucagon Suppression and Glycemic Regulation
Amylin receptor activation suppresses postprandial glucagon secretion from pancreatic α-cells through both direct receptor-mediated effects and indirect vagal/CNS-mediated pathways. In rodent and primate metabolic models, amylin analogue administration has been shown to attenuate glucagon-driven hepatic glucose output and reduce postprandial glycemic excursions, independently of insulin secretion (Verchere et al., Proceedings of the National Academy of Sciences, 1996; Kolterman et al., Diabetes Care, 1996).
